E-Therapeutics PLC
LSE:ETX
E-Therapeutics PLC
LSE:ETX
Price:
9
GBX
-6.74%
Market Closed
Market Cap:
£52.6m
Balance Sheet
Balance Sheet Decomposition
E-Therapeutics PLC
E-Therapeutics PLC
Balance Sheet Decomposition is not available for
E-Therapeutics PLC
E-Therapeutics PLC
Balance Sheet
E-Therapeutics PLC
E-Therapeutics PLC
Currency: GBP
| Jan-2014 | Jan-2015 | Jan-2016 | Jan-2017 | Jan-2018 | Jan-2019 | Jan-2020 | Jan-2021 | Jan-2022 | Jan-2023 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
7
|
2
|
6
|
4
|
7
|
6
|
4
|
13
|
11
|
32
|
|
| Cash |
0
|
0
|
0
|
0
|
0
|
6
|
0
|
0
|
0
|
0
|
|
| Cash Equivalents |
7
|
2
|
6
|
4
|
7
|
0
|
4
|
13
|
11
|
32
|
|
| Short-Term Investments |
36
|
32
|
19
|
10
|
3
|
0
|
0
|
0
|
15
|
0
|
|
| Total Receivables |
1
|
0
|
3
|
3
|
1
|
1
|
1
|
1
|
2
|
2
|
|
| Accounts Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
1
|
0
|
1
|
1
|
2
|
2
|
|
| Other Current Assets |
1
|
0
|
1
|
1
|
1
|
0
|
0
|
0
|
1
|
1
|
|
| Total Current Assets |
45
|
0
|
29
|
18
|
12
|
7
|
5
|
14
|
29
|
34
|
|
| PP&E Net |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
|
| PP&E Gross |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
|
| Accumulated Depreciation |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
|
| Intangible Assets |
1
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Goodwill |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Long-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Assets |
46
N/A
|
0
N/A
|
30
N/A
|
18
-39%
|
12
-34%
|
8
-36%
|
5
-36%
|
14
+199%
|
30
+106%
|
35
+17%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
1
|
1
|
1
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
|
| Accrued Liabilities |
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
1
|
1
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Current Liabilities |
1
|
1
|
1
|
2
|
1
|
1
|
0
|
0
|
1
|
2
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Liabilities |
1
N/A
|
0
N/A
|
1
N/A
|
2
+69%
|
1
-48%
|
1
-31%
|
0
-60%
|
0
+50%
|
2
+319%
|
2
-11%
|
|
| Equity | |||||||||||
| Common Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
|
| Retained Earnings |
20
|
0
|
36
|
49
|
55
|
59
|
61
|
64
|
72
|
80
|
|
| Additional Paid In Capital |
64
|
0
|
65
|
65
|
65
|
65
|
65
|
78
|
99
|
113
|
|
| Total Equity |
45
N/A
|
0
N/A
|
28
N/A
|
16
-44%
|
11
-33%
|
7
-37%
|
5
-34%
|
14
+208%
|
28
+100%
|
33
+19%
|
|
| Total Liabilities & Equity |
46
N/A
|
0
N/A
|
30
N/A
|
18
-39%
|
12
-34%
|
8
-36%
|
5
-36%
|
14
+199%
|
30
+106%
|
35
+17%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
264
|
0
|
264
|
268
|
269
|
269
|
269
|
421
|
515
|
582
|
|
Switch to:
Switch to:
See Also
Discover More
